Andarine (S-4) is an oral selective androgen receptor modulator (SARM), one of the early non-steroidal SARMs, studied by a research group at Ohio State University. It has been studied in rats, has no published human trial, and is not FDA approved.
Also known as: S-4, S4.
For andarine, there is no approved product and no published human trial, so there are no label strengths or studied human amounts.
Andarine is not FDA approved, and we could not find any published trial that gave it to people. FDA says SARMs are unapproved drugs that cannot be legally marketed in the US as dietary supplements or drugs, and lists risks including liver injury and acute liver failure, a higher risk of heart attack or stroke, and effects on fertility. The World Anti-Doping Agency (WADA) names it on its 2026 Prohibited List as a SARM under "other anabolic agents" (S1.2), banned in and out of competition.
In castrated rats (Gao 2005), S-4 restored muscle mass and strength and raised bone density while having much less effect on the prostate than DHT; it also lowered LH and FSH. In female rats with their ovaries removed (Kearbey 2007), it kept bone density and lowered body fat. Rat results often do not carry over to people.
When researchers bought 44 products sold online as SARMs and tested them (Van Wagoner 2017), only 52% contained a SARM (ostarine, LGD-4033 or andarine), 25% contained substances not on the label, and only 41% held the amount the label said.
We could not find a published human half-life or time to peak, so we do not list one. Figures quoted online usually come from animal studies.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator